Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sharing her experiences from both her academic position and from founding and spinning out multiple companies, Dr Angela J. Russell (she/her) Professor of Medicinal Chemistry, illustrates a vision for the future of academic research and the increasing vital importance of enterprise and entrepreneurship skills.


Date? Wednesday 15 November

Time? 12.30 - 14.00. Bring your lunch!

Where? Online via Zoom

Booking link - Academia of the Future

Query? Email Louisa Trevail at: 


Find out how Prof Angela Russell combines the worlds of business and research through her academic position and through the companies she has helped to shape and spin-out. 

Prof Angela Russell embodies being an enterprising academic: she holds a professorial appointment which spans different departments and divisions, and combines the worlds of business and research. Find out how she has navigated these different elements to achieve win: wins and still find time for family life.

Angela Russell

Speaker Bio:

Angela Russell is Professor of Medicinal Chemistry in the Departments of Chemistry and Pharmacology at the University of Oxford. She gained her DPhil in Organic Chemistry in 2004 under the joint supervision of Steve Davies and Tim Perera from Yamanouchi plc (now Astellas Pharma Inc.). In July 2007 she was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry, and became full Professor of Medicinal Chemistry in 2018.

Her work lies at the interface of Chemistry, Biology and Medicine and aims to discover new small molecules and mechanisms to manipulate cell fate and translate them into therapeutic agents, particularly for degenerative diseases.

This work has led to two spin out companies (MuOx in 2013, now part of Summit Therapeutics, and OxStem in 2016) and two clinical trials (in Duchenne muscular dystrophy, DMD, and COVID19). In 2020 she received a Harrington Rare Diseases scholarship award in recognition of her pioneering work to develop a therapy for DMD.